Publications by authors named "Frederic Lehmann"

Claim this Profile
O
Optoelectronic coherent Ising machine for combinatorial optimization problems.
Nickson Mwamsojo, Frederic Lehmann, Kamel Merghem, Badr-Eddine Benkelfat, Yann Frignac

Opt Lett· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
David A Sallman, Tessa Kerre, Violaine Havelange, Xavier Poiré, Philippe Lewalle, Frédéric F Lehmann

Lancet Haematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of tumor-associated antigens in breast cancer subtypes.
Giuseppe Curigliano, Vincenzo Bagnardi, Mariacristina Ghioni, Jamila Louahed, Vincent Brichard, Frederic F Lehmann

Breast· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies.
Lorraine Springuel, Caroline Lonez, Bertrand Alexandre, Eric Van Cutsem, Jean-Pascal H Machiels, Frédéric F Lehmann

BioDrugs· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Susanne H Baumeister, Joana Murad, Lillian Werner, Heather Daley, Helene Trebeden-Negre, Frédéric F Lehmann

Cancer Immunol Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.
David A Sallman, Jason Brayer, Elizabeth M Sagatys, Caroline Lonez, Eytan Breman, Frédéric F Lehmann

Haematologica· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic.
Jean-François Baurain, Caroline Robert, Laurent Mortier, Bart Neyns, Florent Grange, Frédéric F Lehmann

ESMO Open· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Joana M Murad, Susanne H Baumeister, Lillian Werner, Heather Daley, Hélène Trébéden-Negre, Frederic Lehmann

Cytotherapy· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Celyad's novel CAR T-cell therapy for solid malignancies.
Caroline Lonez, Alain Hendlisz, Leila Shaza, Philippe Aftimos, Michaël Vouche, Frédéric F Lehmann

Curr Res Transl Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.
Caroline Lonez, Bikash Verma, Alain Hendlisz, Philippe Aftimos, Ahmad Awada, Frédéric F Lehmann

BMJ Open· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature.
Jean-Jacques Grob, Laurent Mortier, Lionel D'Hondt, Florent Grange, Jean Francois Baurain, Frédéric F Lehmann

ESMO Open· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study.
Jean-Louis Pujol, Tommaso De Pas, Achim Rittmeyer, Eric Vallières, Bartosz Kubisa, Frédéric F Lehmann

J Thorac Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.
Sumitra Thongprasert, Pan-Chyr Yang, Jung Shin Lee, Ross Soo, Olivier Gruselle, Frédéric F Lehmann

Lung Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies, Gennaro Ciliberto, Frédéric F. Lehmann

J Transl Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.
Giuseppe Curigliano, Gilles Romieu, Mario Campone, Thierry Dorval, Lionel Duck, Frédéric F Lehmann

Breast Cancer Res Treat· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
Steven A Limentani, Mario Campone, Thierry Dorval, Giuseppe Curigliano, Richard de Boer, Frédéric F Lehmann

Breast Cancer Res Treat· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.
Jean-Louis Pujol, Johan F Vansteenkiste, Tommaso Martino De Pas, Djordje Atanackovic, Martin Reck, Frédéric F Lehmann

J Thorac Oncol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Fernando Ulloa-Montoya, Jamila Louahed, Benjamin Dizier, Olivier Gruselle, Bart Spiessens, Frédéric F Lehmann

J Clin Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
Johan Vansteenkiste, Marcin Zielinski, Albert Linder, Jubrail Dahabreh, Emilio E Gonzalez, Frédéric F Lehmann

J Clin Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Wim H J Kruit, Stefan Suciu, Brigitte Dreno, Laurent Mortier, Caroline Robert, Frédéric F Lehmann

J Clin Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].
Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, Timothy M Clay, Gloria Broadwater, Frederic Lehmann

J Transl Med· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010".
Paolo A Ascierto, Eleonora De Maio, Stefano Bertuzzi, Giuseppe Palmieri, Ruth Halaban, Frederic F Lehmann

J Transl Med· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Turbo segmentation of textured images.
Frederic Lehmann

IEEE Trans Pattern Anal Mach Intell· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
Margarita Salcedo, Nadège Bercovici, Rachel Taylor, Pierre Vereecken, Séverine Massicard, Frédéric Lehmann

Cancer Immunol Immunother· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.
Gordon C Jayson, Clive Mulatero, Malcolm Ranson, Jamal Zweit, Alan Jackson, Frederic F Lehmann

Eur J Cancer· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis